Lifestylopathy and Ethical Pharmaceuticals: A Halalopathy Perspective
Main Article Content
Abstract
Pharmaceutical ethics is a critical pillar of healthcare, ensuring that medicines are developed, tested, and distributed with integrity, safety, and adherence to ethical principles. In response to the growing demand for ethically conscious healthcare solutions, Lifestylopathy emerges as a holistic framework that integrates ethical, natural, and sustainable approaches to medicine, emphasizing the alignment of pharmaceuticals with cultural, religious, and personal health values. Within this paradigm, Halalopathy addresses the specific ethical and religious concerns of the Muslim community, ensuring that pharmaceuticals comply with Halal (lawful ingredients) and Tayyib (clean and pure process) standards by excluding non-Halal ingredients, preventing cross-contamination, and enforcing transparency in sourcing and production. However, disintegrated Halal certification systems, ingredient verification complexities, and limited awareness among healthcare professionals and consumers present significant barriers to its widespread adoption. Despite these challenges, the growing demand for Halal, Kosher, Vegan, and other ethical pharmaceuticals presents vast opportunities for biotechnological advancements, the development of plant-based excipients, synthetic alternatives, and the establishment of ethical supply chain models. By integrating pharmaceutical ethics with the principles of Lifestylopathy, the industry can meet the needs of an increasingly diverse and ethically conscious consumer base, while maintaining scientific rigor, regulatory compliance, and market competitiveness.
Keywords:
Ethical Pharmaceuticals, Lifestylopathy, Halalopathy, Halal-Tayyib, Vegan, Personalized Medicine
Article Details
How to Cite
ALZEER, Jawad.
Lifestylopathy and Ethical Pharmaceuticals: A Halalopathy Perspective.
Medical Research Archives, [S.l.], v. 13, n. 3, mar. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6384>. Date accessed: 06 apr. 2025.
doi: https://doi.org/10.18103/mra.v3i3.6384.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Saxena K, Balani S, Srivastava P. The relationship among corporate social responsibility, sustainability and organizational performance in pharmaceutical sector: a literature review. Int J Pharm Healthc Mark. 2021;15(4):572-597. https://doi.org/10.1108/ijphm-12-2020-0104
2. Chomać-Pierzecka E. Pharmaceutical companies in the light of the idea of sustainable development—an analysis of selected aspects of sustainable management. Sustainability. 2023;15(11):8889. https://doi.org/10.3390/su15118889
3. Alzeer J. Lifestylopathy as personalized medicine: a holistic approach to health. Med Res Arch. 2025;13(1). https://doi.org/10.18103/mra.v13i1.6209
4. Alzeer J. Halalopathic: a new concept in medicine. J Mol Genet Med. 2018;12(2). https://doi.org/10.4172/1747-0862.1000353
5. Alzeer J. Halalopathy: a science of trust in medicine. J Integr Med. 2019;17(3):150-154. https://doi.org/10.1016/j.joim.2019.03.005
6. Moermond C, Puhlmann N, Brown A, Owen S, Ryan J, Snape J, Kümmerer K. Greener pharmaceuticals for more sustainable healthcare. Environ Sci Technol Lett. 2022;9(9):699-705. https://doi.org/10.1021/acs.estlett.2c00446
7. Ngah A, Ramayah T, Ali M, Khan M. Halal transportation adoption among pharmaceuticals and cosmetics manufacturers. J Islam Mark. 2019;11(6):1619-1639. https://doi.org/10.1108/jima-10-2018-0193
8. Alzeer J. Permissible medicine and rationalization of halal pharma. Halalsphere. 2021;1(1):43-52. https://doi.org/10.31436/hs.v1i1.18
9. Lewis J, Lipworth W, Kerridge I. Ethics, evidence and economics in the pursuit of “personalized medicine”. J Pers Med. 2014;4(2):137-146. https://doi.org/10.3390/jpm4020137
10. Osborne T. Power and persons: on ethical stylisation and person‐centred medicine. Sociol Health Illn. 1994;16(4):515-535. https://doi.org/10.1111/1467-9566.ep11347638
11. Brothers K, Rothstein M. Ethical, legal and social implications of incorporating personalized medicine into healthcare. Pers Med. 2015;12(1):43-51. https://doi.org/10.2217/pme.14.65
12. Alzeer J. Lifestylopathy: unlocking potential by embracing duality and homeostasis for improved healthcare. Int J Regen Med. 2023;1-6. https://doi.org/10.31487/j.rgm.2023.02.02
13. Mohamad T. Individualizing medicinal therapy post heart stent implantation: tailoring for patient factors. Cureus. 2023. https://doi.org/10.7759/cureus.43977
14. Alzeer J. Balancing potential energy and entropy: the foundations of lifestylopathy and homeostasis. J Public Health Emerg. 2024;8:8-8. https://doi.org/10.21037/jphe-23-140
15. Alzeer J. Lifestylopathy: a holistic approach to healthcare. J Altern Med Ther. 2024;1(1):1-4. https://doi.org/10.59462/jamt.1.1.101
16. Olorunsogo T, Balogun O, Ayo-Farai O, Ogundairo O, Maduka C, Okongwu C, Onwumere C. Bioinformatics and personalized medicine in the U.S.: a comprehensive review: scrutinizing the advancements in genomics and their potential to revolutionize healthcare delivery. World J Adv Res Rev. 2024;21(1):335-351. https://doi.org/10.30574/wjarr.2024.21.1.0016
17. Curtis E, Jones R, Tipene‐Leach D, Walker C, Loring B, Paine S, Reid P. Why cultural safety rather than cultural competency is required to achieve health equity: a literature review and recommended definition. Int J Equity Health. 2019;18(1). https://doi.org/10.1186/s12939-019-1082-3
18. Santaló J, Berdasco M. Ethical implications of epigenetics in the era of personalized medicine. Clin Epigenet. 2022;14(1). https://doi.org/10.1186/s13148-022-01263-1
19. Evers K. Personalized medicine in psychiatry: ethical challenges and opportunities. Dialogues Clin Neurosci. 2009;11(4):427-434. https://doi.org/10.31887/dcns.2009.11.4/kevers
20. Alzeer J, Rieder U, Abou Hadeed K. Rational and practical aspects of Halal and Tayyib in the context of food safety. Trends Food Sci Technol. 2018;71:264-267. https://doi.org/10.1016/j.tifs.2017.10.020
21. Alzeer J. Halalopathy: improving potential energy and minimising entropy offer an integrative approach for more effective treatment. MCMS. 2022. https://doi.org/10.55162/mcms.02.027
22. Alzeer J. Holistic approach to personalised medicine: a focus on halalopathy. Halalsphere. 2024;4(2):22-28. https://doi.org/10.31436/hs.v4i2.97
23. Yang C, Smith T, Knowlton A. Cancer patient perspectives on the meaning of healing and the clinician as a healer. Am J Hosp Palliat Med. 2023;41(6):658-663. https://doi.org/10.1177/10499091231191697
24. Alzeer J, Benmerabet H. The development of human personality: a comprehensive overview. Psychol Disord Res. 2023;1-8. https://doi.org/10.31487/j.pdr.2023.01.01
25. Dahlgren S, Reyna-Martínez M, Méte M, Dutton M. Healing narratives from the holistic healing arts retreat. Traumatology Int J. 2020;26(1):40-51. https://doi.org/10.1037/trm0000212
26. Gannotta R, Malik S, Chan A, Urgun K, Hsu F, Vadera S. Integrative medicine as a vital component of patient care. Cureus. 2018. https://doi.org/10.7759/cureus.3098
27. Namisango E, Luyirika E, Matovu L, Berger A. The meaning of healing to adult patients with advanced cancer. Int J Environ Res Public Health. 2023;20(2):1474. https://doi.org/10.3390/ijerph20021474
28. Drury C, Hunter J. The hole in holistic patient care. Open J Nurs. 2016;6(9):776-792. https://doi.org/10.4236/ojn.2016.69078
29. Lee A, Wong Y, Neo X. Personality and psychoneuroimmunology: patient perspectives on mind-body health. JPPR. 2023;1(3):34-40. https://doi.org/10.61838/kman.jppr.1.3.6
30. Alzeer J, Benmerabet H. Potentiality to actuality: quantum physics inspires creative innovation. J Pijar Mipa. 2025;20(1):1-6. https://doi.org/10.29303/jpm.v20i1.8176
31. Jaber D, Hasan H, Alkaderi A, Alkilani A, El-Sharif A. Assessment of the knowledge, attitude, and perception of healthcare providers regarding halal pharmaceuticals. Open Public Health J. 2024;17(1). https://doi.org/10.2174/0118749445296459240322064212
32. Naimat N. Challenges and opportunities in the halal pharmaceutical industry in Malaysia. Inf Manag Bus Rev. 2024;15(4(I)):73-78. https://doi.org/10.22610/imbr.v15i4(i).3565
33. Nekha A. Halal pharmaceutical development in Indonesia. Islam Econ Methodol. 2024;2(2). https://doi.org/10.58968/iem.v2i2.353
34. Ngah A, Ramayah T, Ali M, Khan M. Halal transportation adoption among pharmaceuticals and cosmetics manufacturers. J Islam Mark. 2019;11(6):1619-1639. https://doi.org/10.1108/jima-10-2018-0193
35. Alzeer J, Abou Hadeed K. Halal certification of food, nutraceuticals, and pharmaceuticals in the Arab world. In: Laher I, ed. Handbook of Healthcare in the Arab World. Cham: Springer; 2020. https://doi.org/10.1007/978-3-319-74365-3_36-1
36. Hasnan N. Halal supply chain: challenges of halal certification in Japan. 2023. https://doi.org/10.15405/epsbs.2023.11.02.60
37. Alzeer J, Abou Hadeed K. Ethanol and its halal status in food industries. Trends Food Sci Technol. 2016;58:14-20. https://doi.org/10.1016/j.tifs.2016.10.018
38. Alzeer J, Rieder U, Abou Hadeed K. Good agricultural practices and its compatibility with halal standard. Trends Food Sci Technol. 2020;102:237-241. https://doi.org/10.1016/j.tifs.2020.02.025
39. Alzeer J, Abou Hadeed K, Tufail F. The halal positive list: streamlining the path to certification. Halalsphere. 2025;5(1):1-7. https://doi.org/10.31436/hs.v5i1.109
40. Kasri R, Ahsan A, Widiatmoko D, Hati S. Intention to consume halal pharmaceutical products: evidence from Indonesia. J Islam Mark. 2021;14(3):735-756. https://doi.org/10.1108/jima-06-2021-0192
41. Silalahi S, Fachrurazi F, Fahham A. Factors affecting intention to adopt halal practices: case study of Indonesian small and medium enterprises. J Islam Mark. 2021;13(6):1244-1263. https://doi.org/10.1108/jima-05-2020-0152
42. Al-Kwifi O, Farha A, Ahmed Z. Dynamics of Muslim consumers’ behavior toward halal products. Int J Emerg Mark. 2019;14(4):689-708. https://doi.org/10.1108/ijoem-11-2017-0486
43. Handayani D, Masudin I, Haris A, Restuputri D. Ensuring the halal integrity of the food supply chain through halal suppliers: a bibliometric review. J Islam Mark. 2021;13(7):1457-1478. https://doi.org/10.1108/jima-10-2020-0329
2. Chomać-Pierzecka E. Pharmaceutical companies in the light of the idea of sustainable development—an analysis of selected aspects of sustainable management. Sustainability. 2023;15(11):8889. https://doi.org/10.3390/su15118889
3. Alzeer J. Lifestylopathy as personalized medicine: a holistic approach to health. Med Res Arch. 2025;13(1). https://doi.org/10.18103/mra.v13i1.6209
4. Alzeer J. Halalopathic: a new concept in medicine. J Mol Genet Med. 2018;12(2). https://doi.org/10.4172/1747-0862.1000353
5. Alzeer J. Halalopathy: a science of trust in medicine. J Integr Med. 2019;17(3):150-154. https://doi.org/10.1016/j.joim.2019.03.005
6. Moermond C, Puhlmann N, Brown A, Owen S, Ryan J, Snape J, Kümmerer K. Greener pharmaceuticals for more sustainable healthcare. Environ Sci Technol Lett. 2022;9(9):699-705. https://doi.org/10.1021/acs.estlett.2c00446
7. Ngah A, Ramayah T, Ali M, Khan M. Halal transportation adoption among pharmaceuticals and cosmetics manufacturers. J Islam Mark. 2019;11(6):1619-1639. https://doi.org/10.1108/jima-10-2018-0193
8. Alzeer J. Permissible medicine and rationalization of halal pharma. Halalsphere. 2021;1(1):43-52. https://doi.org/10.31436/hs.v1i1.18
9. Lewis J, Lipworth W, Kerridge I. Ethics, evidence and economics in the pursuit of “personalized medicine”. J Pers Med. 2014;4(2):137-146. https://doi.org/10.3390/jpm4020137
10. Osborne T. Power and persons: on ethical stylisation and person‐centred medicine. Sociol Health Illn. 1994;16(4):515-535. https://doi.org/10.1111/1467-9566.ep11347638
11. Brothers K, Rothstein M. Ethical, legal and social implications of incorporating personalized medicine into healthcare. Pers Med. 2015;12(1):43-51. https://doi.org/10.2217/pme.14.65
12. Alzeer J. Lifestylopathy: unlocking potential by embracing duality and homeostasis for improved healthcare. Int J Regen Med. 2023;1-6. https://doi.org/10.31487/j.rgm.2023.02.02
13. Mohamad T. Individualizing medicinal therapy post heart stent implantation: tailoring for patient factors. Cureus. 2023. https://doi.org/10.7759/cureus.43977
14. Alzeer J. Balancing potential energy and entropy: the foundations of lifestylopathy and homeostasis. J Public Health Emerg. 2024;8:8-8. https://doi.org/10.21037/jphe-23-140
15. Alzeer J. Lifestylopathy: a holistic approach to healthcare. J Altern Med Ther. 2024;1(1):1-4. https://doi.org/10.59462/jamt.1.1.101
16. Olorunsogo T, Balogun O, Ayo-Farai O, Ogundairo O, Maduka C, Okongwu C, Onwumere C. Bioinformatics and personalized medicine in the U.S.: a comprehensive review: scrutinizing the advancements in genomics and their potential to revolutionize healthcare delivery. World J Adv Res Rev. 2024;21(1):335-351. https://doi.org/10.30574/wjarr.2024.21.1.0016
17. Curtis E, Jones R, Tipene‐Leach D, Walker C, Loring B, Paine S, Reid P. Why cultural safety rather than cultural competency is required to achieve health equity: a literature review and recommended definition. Int J Equity Health. 2019;18(1). https://doi.org/10.1186/s12939-019-1082-3
18. Santaló J, Berdasco M. Ethical implications of epigenetics in the era of personalized medicine. Clin Epigenet. 2022;14(1). https://doi.org/10.1186/s13148-022-01263-1
19. Evers K. Personalized medicine in psychiatry: ethical challenges and opportunities. Dialogues Clin Neurosci. 2009;11(4):427-434. https://doi.org/10.31887/dcns.2009.11.4/kevers
20. Alzeer J, Rieder U, Abou Hadeed K. Rational and practical aspects of Halal and Tayyib in the context of food safety. Trends Food Sci Technol. 2018;71:264-267. https://doi.org/10.1016/j.tifs.2017.10.020
21. Alzeer J. Halalopathy: improving potential energy and minimising entropy offer an integrative approach for more effective treatment. MCMS. 2022. https://doi.org/10.55162/mcms.02.027
22. Alzeer J. Holistic approach to personalised medicine: a focus on halalopathy. Halalsphere. 2024;4(2):22-28. https://doi.org/10.31436/hs.v4i2.97
23. Yang C, Smith T, Knowlton A. Cancer patient perspectives on the meaning of healing and the clinician as a healer. Am J Hosp Palliat Med. 2023;41(6):658-663. https://doi.org/10.1177/10499091231191697
24. Alzeer J, Benmerabet H. The development of human personality: a comprehensive overview. Psychol Disord Res. 2023;1-8. https://doi.org/10.31487/j.pdr.2023.01.01
25. Dahlgren S, Reyna-Martínez M, Méte M, Dutton M. Healing narratives from the holistic healing arts retreat. Traumatology Int J. 2020;26(1):40-51. https://doi.org/10.1037/trm0000212
26. Gannotta R, Malik S, Chan A, Urgun K, Hsu F, Vadera S. Integrative medicine as a vital component of patient care. Cureus. 2018. https://doi.org/10.7759/cureus.3098
27. Namisango E, Luyirika E, Matovu L, Berger A. The meaning of healing to adult patients with advanced cancer. Int J Environ Res Public Health. 2023;20(2):1474. https://doi.org/10.3390/ijerph20021474
28. Drury C, Hunter J. The hole in holistic patient care. Open J Nurs. 2016;6(9):776-792. https://doi.org/10.4236/ojn.2016.69078
29. Lee A, Wong Y, Neo X. Personality and psychoneuroimmunology: patient perspectives on mind-body health. JPPR. 2023;1(3):34-40. https://doi.org/10.61838/kman.jppr.1.3.6
30. Alzeer J, Benmerabet H. Potentiality to actuality: quantum physics inspires creative innovation. J Pijar Mipa. 2025;20(1):1-6. https://doi.org/10.29303/jpm.v20i1.8176
31. Jaber D, Hasan H, Alkaderi A, Alkilani A, El-Sharif A. Assessment of the knowledge, attitude, and perception of healthcare providers regarding halal pharmaceuticals. Open Public Health J. 2024;17(1). https://doi.org/10.2174/0118749445296459240322064212
32. Naimat N. Challenges and opportunities in the halal pharmaceutical industry in Malaysia. Inf Manag Bus Rev. 2024;15(4(I)):73-78. https://doi.org/10.22610/imbr.v15i4(i).3565
33. Nekha A. Halal pharmaceutical development in Indonesia. Islam Econ Methodol. 2024;2(2). https://doi.org/10.58968/iem.v2i2.353
34. Ngah A, Ramayah T, Ali M, Khan M. Halal transportation adoption among pharmaceuticals and cosmetics manufacturers. J Islam Mark. 2019;11(6):1619-1639. https://doi.org/10.1108/jima-10-2018-0193
35. Alzeer J, Abou Hadeed K. Halal certification of food, nutraceuticals, and pharmaceuticals in the Arab world. In: Laher I, ed. Handbook of Healthcare in the Arab World. Cham: Springer; 2020. https://doi.org/10.1007/978-3-319-74365-3_36-1
36. Hasnan N. Halal supply chain: challenges of halal certification in Japan. 2023. https://doi.org/10.15405/epsbs.2023.11.02.60
37. Alzeer J, Abou Hadeed K. Ethanol and its halal status in food industries. Trends Food Sci Technol. 2016;58:14-20. https://doi.org/10.1016/j.tifs.2016.10.018
38. Alzeer J, Rieder U, Abou Hadeed K. Good agricultural practices and its compatibility with halal standard. Trends Food Sci Technol. 2020;102:237-241. https://doi.org/10.1016/j.tifs.2020.02.025
39. Alzeer J, Abou Hadeed K, Tufail F. The halal positive list: streamlining the path to certification. Halalsphere. 2025;5(1):1-7. https://doi.org/10.31436/hs.v5i1.109
40. Kasri R, Ahsan A, Widiatmoko D, Hati S. Intention to consume halal pharmaceutical products: evidence from Indonesia. J Islam Mark. 2021;14(3):735-756. https://doi.org/10.1108/jima-06-2021-0192
41. Silalahi S, Fachrurazi F, Fahham A. Factors affecting intention to adopt halal practices: case study of Indonesian small and medium enterprises. J Islam Mark. 2021;13(6):1244-1263. https://doi.org/10.1108/jima-05-2020-0152
42. Al-Kwifi O, Farha A, Ahmed Z. Dynamics of Muslim consumers’ behavior toward halal products. Int J Emerg Mark. 2019;14(4):689-708. https://doi.org/10.1108/ijoem-11-2017-0486
43. Handayani D, Masudin I, Haris A, Restuputri D. Ensuring the halal integrity of the food supply chain through halal suppliers: a bibliometric review. J Islam Mark. 2021;13(7):1457-1478. https://doi.org/10.1108/jima-10-2020-0329